Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMPL0BA)

Drug Name
ANDROSTENEDONE Drug Info
Synonyms
androsta-1,4-diene-3,17-dione; Boldione; 1,4-Androstadiene-3,17-dione; 897-06-3; Androstadienedione; 1-Dehydroandrostenedione; NSC 49080; UNII-2166Q8568W; EINECS 212-977-2; ANDROSTA-1,4-DIEN-3,17-DIONE; CHEBI:40799; LUJVUUWNAPIQQI-QAGGRKNESA-N; Androstra-1,4-diene-3,17-dione; 2166Q8568W; (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-dione; (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione; ANB
Cross-matching ID
PubChem CID
13472
ChEBI ID
CHEMBL1078534
CAS Number
CAS 897-06-3
TTD Drug ID
D0W9PF

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Epithelial cell signaling in Helicobacter pylori infect... 1.65 3.47e-1 62/70 (88.57%) CXCL8;PAK1;ATP6V1G1;...
Pathogenic Escherichia coli infection 1.62 3.08e-1 152/197 (77.16%) CXCL8;PAK1;TNFSF10;...
NOD-like receptor signaling pathway 1.61 2.54e-1 145/181 (80.11%) CXCL8;ITPR1;DEFB4A;...
Melanogenesis 1.59 2.51e-1 74/101 (73.27%) LEF1;WNT5A;TYR;...
Neomycin, kanamycin and gentamicin biosynthesis 1.56 2.55e-1 5/5 (100%) HK2;HK3
Sphingolipid metabolism 1.56 2.21e-1 32/49 (65.31%) DEGS1;UGCG;PLPP1;...
Steroid biosynthesis 1.50 3.28e-1 19/20 (95%) SC5D;SOAT1;MSMO1;...
Neutrophil extracellular trap formation 1.49 3.14e-1 101/189 (53.44%) ELANE;CYBA;MPO;...
Progesterone-mediated oocyte maturation 1.48 3.16e-1 75/100 (75%) CDK2;CDC25A;PIK3CB;...
DNA replication 1.46 3.42e-1 34/36 (94.44%) POLE2;RPA2;RFC2;...
Mismatch repair 1.45 3.32e-1 22/23 (95.65%) RPA2;RFC2;POLD4;...
Cell cycle 1.43 3.54e-1 110/124 (88.71%) ABL1;CDK2;DBF4;...
Spinocerebellar ataxia 1.43 3.39e-1 128/143 (89.51%) ITPR1;MAP3K5;PSMA1;...
Parkinson disease 1.38 4.89e-1 176/249 (70.68%) ITPR1;COX7B;MAP3K5;...
Tight junction 1.35 5.03e-1 130/169 (76.92%) MAP3K5;RDX;CLDN8;...
IL-17 signaling pathway 1.35 5.03e-1 84/94 (89.36%) CXCL8;LCN2;S100A9;...
Amoebiasis 1.34 4.90e-1 99/102 (97.06%) CXCL8;IL1R1;ARG1;...
Kaposi sarcoma-associated herpesvirus infection 1.32 5.08e-1 172/193 (89.12%) CXCL8;CLEC2B;LEF1;...
Nucleotide excision repair 1.32 5.12e-1 40/47 (85.11%) CETN2;CUL4B;POLE2;...
Huntington disease 1.31 5.05e-1 233/306 (76.14%) ITPR1;COX7B;MAP3K5;...
C-type lectin receptor signaling pathway 1.31 5.00e-1 93/104 (89.42%) PAK1;ITPR1;NFATC3;...
Human immunodeficiency virus 1 infection 1.28 5.07e-1 189/212 (89.15%) PAK1;ITPR1;NFATC3;...
Alzheimer disease 1.28 4.92e-1 279/369 (75.61%) ITPR1;COX7B;MAP3K5;...
Cellular senescence 1.28 4.80e-1 139/156 (89.1%) CXCL8;ITPR1;NFATC3;...
Biosynthesis of unsaturated fatty acids 1.26 5.10e-1 21/27 (77.78%) BAAT;SCP2;HSD17B4;...
GnRH signaling pathway 1.26 5.05e-1 80/93 (86.02%) ITPR1;MAP2K6;MAP3K1;...
Adherens junction 1.26 4.95e-1 63/71 (88.73%) LEF1;SRC;CDC42;...
Oocyte meiosis 1.25 4.93e-1 90/129 (69.77%) ITPR1;CDK2;AR;...
Terpenoid backbone biosynthesis 1.25 4.93e-1 18/22 (81.82%) ACAT2;HMGCS1;IDI1;...
Primary bile acid biosynthesis 1.25 4.85e-1 15/17 (88.24%) AMACR;BAAT;SCP2;...
Coronavirus disease -1.32 4.14e-1 215/232 (92.67%) IFNA14;CYBB;C9;...
Central carbon metabolism in cancer -1.33 4.15e-1 67/70 (95.71%) PFKM;ERBB2;G6PD;...
Cell adhesion molecules -1.34 3.95e-1 118/148 (79.73%) CDH1;ITGAM;ITGAV;...
Adrenergic signaling in cardiomyocytes -1.34 4.06e-1 130/150 (86.67%) AGTR1;ATP2A2;MYL3;...
Leishmaniasis -1.36 3.74e-1 67/77 (87.01%) IL1A;ITGAM;FCGR2A;...
Glyoxylate and dicarboxylate metabolism -1.36 3.79e-1 23/30 (76.67%) MDH1;MMUT;PCCA;...
Pertussis -1.37 3.71e-1 64/76 (84.21%) ITGB2;SERPING1;C1R;...
PI3K-Akt signaling pathway -1.43 2.41e-1 317/354 (89.55%) PPP2R2B;IFNA14;GYS2;...
alpha-Linolenic acid metabolism -1.44 2.23e-1 17/25 (68%) PLA2G4C;PLAAT3
Arginine biosynthesis -1.45 2.30e-1 17/22 (77.27%) GOT2;GOT1;GLS2;...
B cell receptor signaling pathway -1.46 2.23e-1 71/81 (87.65%) LILRB5;PLCG2;IFITM1;...
ECM-receptor interaction -1.49 1.74e-1 80/88 (90.91%) COL9A1;THBS1;THBS3;...
Intestinal immune network for IgA production -1.51 1.54e-1 38/48 (79.17%) HLA-DPB1;IL5;TGFB1;...
Cardiac muscle contraction -1.51 1.60e-1 64/87 (73.56%) ATP2A2;MYL3;ATP1A1;...
D-Glutamine and D-glutamate metabolism -1.53 1.44e-1 5/5 (100%) DGLUCY;GLS2;GLS
Glycine, serine and threonine metabolism -1.56 1.16e-1 31/40 (77.5%) CTH;ALDH7A1;SHMT2;...
Malaria -1.57 1.17e-1 44/50 (88%) ITGB2;TGFB1;TGFB3;...
Mineral absorption -1.59 1.09e-1 48/60 (80%) ATP1A2;MT1H;SLC39A4;...
Viral protein interaction with cytokine and cytokine re... -1.60 1.05e-1 84/100 (84%) CCL2;CCR9;CCL22;...
Hypertrophic cardiomyopathy -1.61 1.09e-1 81/90 (90%) ATP2A2;MYL3;CACNA2D1;...
Proximal tubule bicarbonate reclamation -1.63 9.85e-2 21/23 (91.3%) ATP1A2;GLS2;AQP1;...
Dilated cardiomyopathy -1.64 1.08e-1 86/96 (89.58%) ATP2A2;MYL3;ADCY3;...
Calcium signaling pathway -1.64 1.21e-1 213/240 (88.75%) NTRK1;AGTR1;NGF;...
Staphylococcus aureus infection -1.65 1.17e-1 72/95 (75.79%) ITGAM;KRT12;FCGR2A;...
Alanine, aspartate and glutamate metabolism -1.69 9.12e-2 27/37 (72.97%) GOT2;GOT1;ALDH5A1;...
Systemic lupus erythematosus -1.70 9.75e-2 45/135 (33.33%) ACTN4;FCGR2A;HLA-DPB1;...
Cortisol synthesis and secretion -1.75 7.21e-2 58/65 (89.23%) NR0B1;ADCY3;CACNA1C;...
Complement and coagulation cascades -1.77 6.30e-2 76/85 (89.41%) PLAU;F2RL2;ITGB2;...
Primary immunodeficiency -1.78 8.46e-2 33/38 (86.84%) RAG2;AICDA;PTPRC;...
Melanoma -1.85 7.96e-2 68/72 (94.44%) MET;PDGFC;E2F2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H